1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: EGF-R Antibodies –Biosimilars and Biosuperiors

EGF-R Antibodies –Biosimilars and Biosuperiors
The present Competitive Intelligence Report about EGF-R Antibodies –Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
At present, there are two approved and marketed EGF-R antibodies in regulated markets. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies.
The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: EGF-R Antibodies -Biosimilars and Biosuperiors
Competitor Analysis: EGF-R Antibodies -Biosimilars and Biosuperiors
Table of Contents
1. EGF-R Antibodies -Biosimilars and Biosuperiors

Marketed EGF-R Antibodies

-           Erbitux Sales and Pipeline

-           Vectibix Sales and Pipeline

-           Nimotuzumab Pipeline

EGF-R Antibody Biobetters/Biosuperiors

-           Engineered EGF-R Antibodies

-           Bi- and Multispecific EGF-R Antibodies

-           EGF-R Antibody-Drug Conjugates

EGF-R Antibody Biosimilars

-           Cetuximab Biosimilars

-           Panitumumab Biosimilars

2.  Corporate EGF-R Antibody Biosimilar and Biobetter Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Monoclonal Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Monoclonal Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Monoclonal Antibody Therapeutics Market: Overview Monoclonal antibodies are a type of biological therapy used in the treatment serious conditions such as cancer, rheumatoid arthritis, Crohn’s ...

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, ...

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

  • $ 4995
  • Industry report
  • December 2016
  • by GBI Research

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments ...


Download Unlimited Documents from Trusted Public Sources

Insulin Market and Diabetes Statistics in the US

  • February 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Hormone Market in the US

  • February 2017
    9 pages
  • Hormone  

    Cytokine  

  • United States  

View report >

Therapy Market and Monoclonal Antibody Market in Japan

  • February 2017
    6 pages
  • Therapy  

    Monoclonal Anti...  

  • Japan  

View report >

Related Market Segments :

Monoclonal Antibody

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.